SODIUM ACETATE Drug Patent Profile
✉ Email this page to a colleague
When do Sodium Acetate patents expire, and what generic alternatives are available?
Sodium Acetate is a drug marketed by Amneal, Extrovis, Fresenius Kabi Usa, Hikma, Hospira, Milla Pharms, and Somerset Theraps Llc. and is included in seven NDAs.
The generic ingredient in SODIUM ACETATE is sodium acetate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the sodium acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sodium Acetate
A generic version of SODIUM ACETATE was approved as sodium acetate by HOSPIRA on May 4th, 1983.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SODIUM ACETATE?
- What are the global sales for SODIUM ACETATE?
- What is Average Wholesale Price for SODIUM ACETATE?
Summary for SODIUM ACETATE
| US Patents: | 0 |
| Applicants: | 7 |
| NDAs: | 7 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 230 |
| Drug Prices: | Drug price information for SODIUM ACETATE |
| What excipients (inactive ingredients) are in SODIUM ACETATE? | SODIUM ACETATE excipients list |
| DailyMed Link: | SODIUM ACETATE at DailyMed |
Pharmacology for SODIUM ACETATE
| Drug Class | Osmotic Laxative |
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
Anatomical Therapeutic Chemical (ATC) Classes for SODIUM ACETATE
US Patents and Regulatory Information for SODIUM ACETATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 218469-003 | Mar 2, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Somerset Theraps Llc | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 219826-002 | Sep 18, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Hikma | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 216920-001 | Mar 15, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Extrovis | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 220274-001 | Apr 17, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
